Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 5, 1996, Pages 482-488

  Frissen, P H Jos ^a   Weverling, Gerrit Jan ^b   Endert, Erik ^b   Jansen, Jaap ^b   Sauerwein, Hans P ^b   Lange, Joep M A ^b  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Interferon ; Predictive markers; Soluble tumor necrosis factor receptors; Survival; Symptomatic human immunodeficiency virus infection; Zidovudine

Indexed keywords

ALPHA INTERFERON; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029813652     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199608150-00007     Document Type: Article

References (30)

1. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow-up of the San Francisco General Hospital Cohort. Br Med J 1987;296:745-50.
2. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989;321:1141-8.
3. Lange JMA, De Wolf F, Goudsmit J. Markers for progression in HIV infection. AIDS 1989;3(suppl)1:S153-60.
4. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
5. Mildvan D. Clinical validation of virological and immunological assays. 17th AIDS Clinical Trials Group Meeting. Washington D.C., December 4-8, 1993.
6. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405-17.
7. Engelberts I, Stephens S, Francot GJM, Van der Linden CJ, Buurman WA. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991;338:515-6.
8. Godfried MH, Van der Poll T, Jansen J, et al. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. AIDS 1993;7:33-6.
9. Hohman H-P, Remy R, Brockhaus M, Van Loon APGM. Two different cell types have different major receptors for human tumor necrosis factor (TNF-alpha). J Biol Chem 1989;264:14927-34.
10. Zangerle R, Gallati H, Sarcletti M, et al. Increased concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J AIDS 1994;7:79-85.
11. Aukurst P, Liabakk N-B, Mueller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169: 420-4.
12. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
13. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548-61.
14. Godfried MH, Van Der Poll T, Weverling GJ, et al. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:739-45.
15. Godfried MH, Van der Poll T, Mulder JW, et al. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J AIDS Hum Retrovirol 1995;10:531-9.
16. Centers for Disease Control. Current trends: classification system for human T lymphotropic virus type III/lymphadenopathy associated virus infections. MMWR 1986;35: 334-9.
17. Frissen PHJ, Van der Ende ME, Ten Napel CHH, et al. Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:1351-5.
18. Sackett DL, Haynes RB, Tugwell P. The interpretation of diagnostic data. Clinical epidemiology. A basic science for clinical medicine. Boston/Toronto: Little, Brown, 1985:59-138.
19. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(suppl 1):1S-15S.
20. Jacobson MA, Bacchetti P, Kolokathis A, et al. Surrogate markers for survival in patients with AIDS and AIDS-related complex treated with zidovudine. Br Med J 1991;302:73-8.
21. Bacchetti P, Moss AR, Andrews JC, Jacobson MA. Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine. J AIDS 1992;5:732-6.
22. DeGruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J AIDS 1993;6:359-65.
23. Easterbrook PJ, Emami J, Gazzard B. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. AIDS 1993;7:959-67.
24. Simberkoff MS, Hartigan PA, Hamilton JD, et al. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment: report of a Veterans Affairs Cooperative study. J AIDS Hum Retrovirol 1996;11:142-50.
25. Girardin E, Roux-Lombard P, Grau GE, et al. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992;76:20-3.
26. Aderka D, Wysenbeek A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-19.
27. Lau AS, Der SD, Read SE, Williams BRG. Regulation of tumor necrosis factor receptor expression by acid-labile interferon-alpha from AIDS sera. AIDS Res Hum Retroviruses 1991;7:545-52.
28. Pandita R, Pocsik E, Aggarwal BB. Interferon-gamma induces cell surface expression for both types of tumor necrosis factor receptors. FEBS Lett 1992;312:87-90.
29. Aggarwal BB, Pandita R. Both type I and II interferons down-regulate human tumor necrosis factor receptors in human hepatocellular carcinoma cell line Hep G2. Role of protein kinase C. FEBS Lett 1994;337:99-102.
30. Bass HZ, Hardy WD, Mitsuyasu RT, et al. The effect of zidovudine treatment on serum neopterin and beta-2 microglobulin levels in mildly symptomatic HIV type 1 seropositive individuals. J AIDS 1992;5:215-21.